Considering that CTD-PAH is a group of inflammatory autoimmune diseases and that HIF-1α additionally contributes to pulmonary hypertension via mechanisms other than inflammation, such as glycolysis and cell survival (49–51), it is plausible that pulmonary vascular succinate handling represents a physiologically important marker of PAH. This evidence concerns the gene HIF1A and pulmonary arterial hypertension.